Astaxanthin supplementation study Not Applicable
Conditions
Interventions
1. Higher astaxanthin content group: Ingesting supplement containing 1mg astaxanthin
2. Lower astaxanthin content group: Ingesting supplement containing 3mg astaxanthin
3. Control group: placebo
Tota
Sponsors
Yamaha Motor Co., Ltd (Japan)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female, aged 20-69 2. Blood Test Value: Total Cholesterol: 200-260mg/dL or low density lipoprotein (LDL)-cholesterol: 120-180mg/dL
Exclusion criteria
Exclusion criteria: 1. All subjects who are capable to cause serious allergy symptoms to foods and medical drugs 2. They ingest medical drugs or herbal medicines which will affect result of test 3. They continuously ingest foods prepared with astaxanthin during past one month or even today 4. They regularly ingest health foods and beverages which profess similar effects with test foods 5. They drink alcohol more four or more days per week in the past three months 6. They have a history of circulatory disease, nephritis and hepatitis 7. They have digestive disease or have experienced the surgery of the digestive organs (except of surgery of appendicitis) 8. They exceed more than 2.5 of the standard value of Aspartate transaminase (AST), Alanine aminotransferase (ALT ) and gamma-glutamyltranspeptidase (?-GT) 9. They exceed more than 9.0 ml/g of the uric acid 10. They have serious anemia 11. They participate in other clinical trial with human subjects 12. They are judged by the principal investigator to participate in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Biological Antioxidant Potential (BAP) test 2. Determination of Reactive Oxygen Metabolites (d-ROMs) test Measured at Visit 1: Screening, Visit 2: Week 1, Visit 3: Weeks 4, Visit 4: Weeks 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Peroxidized phospholipid measured at Visit 1: Screening, Visit 2: Week 1, Visit 3: Weeks 4, Visit 4: Weeks 12 | — |
Countries
Japan
Outcome results
None listed